<DOC>
	<DOCNO>NCT00025194</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ixabepilone estramustine , use different way stop tumor cell divide stop grow die . It yet know whether BMS-247550 effective without estramustine treat prostate cancer . PURPOSE : This randomized phase I/II trial study best dose ixabepilone give together estramustine see well give ixabepilone together estramustine work compare ixabepilone alone treat patient progressive prostate cancer .</brief_summary>
	<brief_title>Ixabepilone With Without Estramustine Treating Patients With Progressive Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ixabepilone combine estramustine patient progressive androgen-independent adenocarcinoma prostate . ( Phase I ) - Compare safety efficacy ixabepilone without estramustine patient population . ( Phase II ) - Correlate clinical outcome reverse transcriptase-polymerase chain reaction-based assay prostate-specific antigen mRNA patient treat regimen . OUTLINE : This dose-escalation study ixabepilone ( phase I ) follow randomize , multicenter study ( phase II ) . - Phase I : Patients receive ixabepilone IV 3 hour day 2 oral estramustine 3 time daily day 1-5 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ixabepilone maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . - Phase II : Patients randomize 1 2 treatment arm . - Arm I : Patients receive ixabepilone IV 3 hour MTD day 2 estramustine phase I . - Arm II : Patients receive ixabepilone IV 3 hour MTD day 1 . Treatment arm repeat phase I . Patients follow every 12 week disease progression . PROJECTED ACCRUAL : A total 3-12 patient accrued phase I study total 44-92 patient ( 22-46 per treatment arm ) accrue phase II study within 12-18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma prostate Must disease progression meet 1 follow criterion : Rising prostatespecific antigen ( PSA ) least 3 consecutive measurement take 1 week apart Measurable disease , define new progressive soft tissue mass CT scan MRI New metastatic lesion radionuclide bone scan The recent PSA must least 4 ng/mL measurable disease present Ineligible sole manifestation progressive disease increase diseaserelated symptom Serum testosterone great 50 ng/mL One follow therapy maintenance castrate status require : Must continue gonadotropinreleasing hormone analog ( e.g. , leuprolide goserelin ) maintain castrate level serum testosterone Developed disease progression discontinuation antiandrogen part firstline hormonal therapy Prior surgical orchiectomy Developed disease progression discontinuation megestrol No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No history bleed disorder would preclude anticoagulation warfarin Hepatic : Bilirubin normal AST/ALT great 2.5 time upper limit normal ( ULN ) PT/PTT normal ( unless anticoagulated reason [ e.g. , atrial fibrillation ] ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No significant cardiovascular disease No symptomatic congestive heart failure No New York Heart Association class III IV heart disease No active unstable angina pectoris No cardiac arrhythmia No myocardial infarction within past 6 month No history hemorrhagic thrombotic cerebrovascular accident deep venous thrombosis within past 6 month Pulmonary : No pulmonary embolism within past 6 month Other : Fertile patient must use effective contraception No history allergic reaction compound similar chemical biological composition epothilones No history recent gastrointestinal bleeding would preclude anticoagulation warfarin No concurrent active malignancy except nonmelanomatous skin cancer Disease consider currently active completely treat less 30 % risk relapse No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent routine filgrastim ( GCSF ) sargramostim ( GMCSF ) except neutropenic fever No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : No prior palliative radiotherapy 25 % bone marrow No prior radioisotope therapy strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium No concurrent therapeutic radiotherapy Concurrent focal radiotherapy palliation bone diseaserelated symptom allow investigator 's discretion Surgery : See Disease Characteristics At least 4 week since prior major surgery Other : No concurrent anticancer investigational commercial agent therapies No concurrent herbal , alternative , food supplement ( e.g. , PCSPES , saw palmetto , St. John 's Wort ) No concurrent combination antiretroviral therapy HIVpositive patient No initiation bisphosphonates immediately study Concurrent bisphosphonates allow developed disease progression stable dos Concurrent daily multivitamin allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>